Aims: The association of telomere length (TL) and coronary heart disease (CHD) is still debated, and there is a lack of dose-response meta-analyses on this issue. The aim is therefore to integrate existing evidence on the association between TL and CHD risk and explore the dose-response relationship between them.
Data Synthesis: PubMed, EMBASE, and Web of Science were searched for relevant studies up to September 2024. Meta-analysis was performed using a random-effects model, with data presented as RRs and 95 % CIs. Restricted cubic splines were used to assess linear and nonlinear associations. Subgroup analysis and meta-regression were performed to explore sources of heterogeneity. Fourteen articles (8 prospective cohort studies, 2 case-cohort studies, 2 case-control studies, and 2 cross-sectional studies) were finally included in the meta-analysis, with a total sample size of 199,562 participants and 25,752 cases. For CHD, the total RR for the highest TL group compared to the lowest TL group was 0.69 (95 % CI: 0.61, 0.78, I = 64.5 %). For every 1 kilobase pair (kbp) increase in TL, the CHD risk decreased by 23 % (RR = 0.77, 95 % CI: 0.69, 0.87, I = 89.0 %). The nonlinearity test indicated a linear association between TL and CHD risk (P = 0.930). Sensitivity analyses indicated that the results were robust.
Conclusions: The meta-analysis showed a linear relationship between TL and CHD. People with low TL may be more likely to develop CHD than those with high TL. The association between the two did not change in a wide range of populations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.numecd.2024.103830 | DOI Listing |
Nutr Metab Cardiovasc Dis
December 2024
Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, People's Republic of China. Electronic address:
Aims: The association of telomere length (TL) and coronary heart disease (CHD) is still debated, and there is a lack of dose-response meta-analyses on this issue. The aim is therefore to integrate existing evidence on the association between TL and CHD risk and explore the dose-response relationship between them.
Data Synthesis: PubMed, EMBASE, and Web of Science were searched for relevant studies up to September 2024.
Nutr Metab Cardiovasc Dis
November 2024
Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China. Electronic address:
Background And Aims: Patients receiving statin therapy still suffer from adverse cardiovascular events. Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is a newly proposed concept that shares common metabolic risk factors with cardiovascular disease. This study aimed to investigate the association between MAFLD and adverse cardiovascular outcomes in coronary heart disease (CHD) patients with LDL-C<1.
View Article and Find Full Text PDFHeart Rhythm
January 2025
Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China. Electronic address:
Nutrients
December 2024
Department of Prenatal Cardiology, Polish Mother's Memorial Hospital Research Institute in Lodz, 93-338 Lodz, Poland.
Introduction: The relationship between diet of mothers, including supplementation of vitamin D and Long Chain Polyunsaturated Fatty Acids (LC-PUFA), and the prevalence of congenital heart defects (CHD) in the fetus has not been sufficiently studied. The aim of the study was to investigate the relationship between the intake of vitamin D and LC-PUFA by mother (from diet and with supplementation, including its time of implementation and applied dose), and the risk of CHD in the fetus.
Methods: This was a case-control study with the participation of a total of 79 women with prenatally diagnosed CHD in the fetus and 121 women without CHD in the fetus.
Molecules
December 2024
Laboratory of Clinical Chemistry, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
Coronary heart disease (CHD) is the leading cause of morbidity and mortality worldwide despite significant improvements in diagnostic modalities. Emerging evidence suggests that erythrocytes, or red blood cells (RBCs), are one of the most important contributors to the events implicated in atherosclerosis, although the molecular mechanisms behind it are under investigation. We used NMR-based lipidomic technology to investigate the RBC lipidome in patients with CHD compared to those with normal coronary arteries (NCAs), all angiographically documented, and its correlation with coronary artery stenosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!